Viridian Therapeutics Inc

NASDAQ:VRDNUnited States

Viridian Therapeutics, Inc. is a biotechnology company focused on discovering and developing medicines for serious and rare diseases. The Company is engaged in developing three product candidates, VRDN-001, VRDN-002, and VRDN-003, that is developed for intravenous (IV) or subcutaneous administration to treat patients who suffer from thyroid eye disease (TED). Its lead product candidate, VRDN-001, is a differentiated humanized monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the TED. It has initiated a Phase I/II clinical trial of VRDN-001. Its second product candidate, VRDN-002, is a distinct IGF-1R antibody that incorporates half-life extension technology, and is designed to support administration as a convenient, low volume, subcutaneous injection to treat patients who suffer from TED. VRDN-003 is an anti-IGF-1R monoclonal antibody with the same amino acid sequence as VRDN-001.

Contact Information

Headquarters

221 CRESCENT STREET, BLDG. 17, SUITE 401WALTHAM, MA, United States 02453

Phone

617-272-4600

Fax

302-655-5049

Executives

Independent Chairman of the Board

Tomas Kiselak

President, Chief Executive Officer, Director

Stephen Mahoney

Principal Financial and Accounting Officer

Seth Harmon

Chief Operating Officer

Thomas Beetham

Chief Medical Officer

Barrett Katz